Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2009 | Original Article

Quantification of (R)-[¹¹C]PK11195 binding in rheumatoid arthritis

Authors: M. A. Kropholler, R. Boellaard, E. H. Elzinga, C. J. van der Laken, K. Maruyama, R. W. Kloet, A. E. Voskuyl, B. A. C. Dijkmans, A. A. Lammertsma

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2009

Abstract

Purpose

Rheumatoid arthritis (RA) involves migration of macrophages into inflamed areas. (R)-[¹¹C]PK11195 binds to peripheral benzodiazepine receptors, expressed on macrophages, and may be used to quantify inflammation using positron emission tomography (PET). This study evaluated methods for the quantification of (R)-[¹¹C]PK11195 binding in the knee joints of RA patients.

Methods

Data from six patients with RA were analysed. Dynamic PET scans were acquired in 3-D mode following (R)-[¹¹C]PK11195 injection. During scanning arterial radioactivity concentrations were measured to determine the plasma (R)-[¹¹C]PK11195 concentrations. Data were analysed using irreversible and reversible one-tissue and two-tissue compartment models and input functions with various types of metabolite correction. Model preferences according to the Akaike information criterion (AIC) and correlations between measures were evaluated. Correlations between distribution volume (V_d) and standardized uptake values (SUV) were evaluated.

Results

AIC indicated optimal performance for a one-tissue reversible compartment model including blood volume. High correlations were observed between V_d obtained using different input functions (R ²=0.80–1.00) and between V_d obtained with one- and two-tissue reversible compartment models (R ²=0.75–0.94). A high correlation was observed between optimal V_d and SUV after injection (R ²=0.73).

Conclusion

(R)-[¹¹C]PK11195 kinetics in the knee were best described by a reversible single-tissue compartment model including blood volume. Applying metabolite corrections did not increase sensitivity. Due to the high correlation with V_d, SUV is a practical alternative for clinical use.

Ju JH, Kang KY, Kim IJ, Yoon JU, Kim HS, Park SH, Kim HY. Visualization and localization of rheumatoid knee synovitis with FDG-PET/CT images. Clin Rheumatol 2008; doi:10.1007/s10067-008-0849-5

Elzinga EH, van der Laken CJ, Comans EF, Lammertsma AA, Dijkmans BA, Voskuyl AE. 2-Deoxy-2-[F-18]fluoro-D-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol 2007;9:357–60.PubMedCrossRef

Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology 2007;46:672–7.PubMedCrossRef

Beckers C, Ribbens C, André B, Marcelis S, Kaye O, Mathy L, et al. Assessment of disease activity in rheumatoid arthritis with [18]F-FDG PET. J Nucl Med 2004;45:956–64.PubMed

Zavala F, Lenfant M. Benzodiazepines and PK 11195 exert immunomodulating activities by binding on a specific receptor on macrophages. Ann N Y Acad Sci 1987;496:240–9.PubMedCrossRef

Jones HA, Valind SO, Clark IC, Bolden GE, Krausz T, Schofield JB, et al. Kinetics of lung macrophages monitored in vivo following particulate challenge in rabbits. Toxicol Appl Pharmacol 2002;183:46–54.PubMedCrossRef

Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123(Pt 11):2321–37.PubMedCrossRef

Price CJ, Wang D, Menon DK, Guadagno JV, Cleij M, Fryer T, et al. Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke 2006;37:1749–53.PubMedCrossRef

Chen MK, Guilarte TR. Imaging the peripheral benzodiazepine receptor response in central nervous system demyelination and remyelination. Toxicol Sci 2006;91:532–9.PubMedCrossRef

10.

Iversen P, Hansen DA, Bender D, Rodell A, Munk OL, Cumming P, et al. Peripheral benzodiazepine receptors in the brain of cirrhosis patients with manifest hepatic encephalopathy. Eur J Nucl Med Mol Imaging 2006;33:810–6PubMedCrossRef

11.

Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [(11)C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006;21:404–12.PubMedCrossRef

12.

Cagnin A, Kassiou M, Meikle SR, Banati RB. In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurol Scand Suppl 2006;185:107–14.PubMedCrossRef

13.

Hammoud DA, Endres CJ, Chander AR, Guilarte TR, Wong DF, Sacktor NC, et al. Imaging glial cell activation with [(11)C]-R-PK11195 in patients with AIDS. J Neurovirol 2005;11:346–55.PubMedCrossRef

14.

Versijpt J, Debruyne JC, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler 2005;11:127–34.PubMedCrossRef

15.

Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005;57:168–75.PubMedCrossRef

16.

Henkel K, Karitzky J, Schmid M, Mader I, Glatting G, Unger JW, et al. Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration. Mov Disord 2004;19:817–21.PubMedCrossRef

17.

Schuitemaker A, Berckel BNM, Kropholler MA, Kloet RW, Jonker C, Scheltens P, et al. Evaluation of methods for generating parametric (R)-[11C]PK11195 binding images. J Cereb Blood Flow Metab 2007;27:1603–15.PubMedCrossRef

18.

Kropholler MA, Boellaard R, Schuitemaker A, van Berckel BN, Luurtsema G, Windhorst AD, et al. Development of a tracer kinetic plasma input model for (R)-[11C]PK11195 brain studies. J Cereb Blood Flow Metab 2005;25(7):842–51.PubMedCrossRef

19.

Kropholler MA, Boellaard R, Schuitemaker A, Folkersma H, Berckel BNM, Lammertsma AA. Evaluation of reference tissue models for the analysis of [11C](R)-PK11195 studies. J Cereb Blood Flow Metab 2006;26:1431–41.PubMedCrossRef

20.

Jones HA, Hamacher K, Clark JC, Schofield JB, Krausz T, Haslett C, et al. Positron emission tomography in the quantification of cellular and biochemical responses to intrapulmonary particulates. Toxicol Appl Pharmacol 2005;207(2 Suppl):230–6PubMedCrossRef

21.

Jones HA, Marino PS, Shakur BH, Morrell NW. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J 2003;21:567–73.PubMedCrossRef

22.

Hardwick MJ, Chen MK, Baidoo K, Pomper MG, Guilarte TR. In vivo imaging of peripheral benzodiazepine receptors in mouse lungs: a biomarker of inflammation. Mol Imaging 2005;4:432–8.PubMed

23.

Charbonneau P, Syrota A, Crouzel C, Valois JM, Prenant C, Crouzel M. Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography. Circulation 1986;73:476–83.PubMed

24.

Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.PubMedCrossRef

25.

Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729–40.PubMedCrossRef

26.

Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997;38:1614–23.PubMed

27.

Adam LE, Jears J, Ostertag H, Trojan H, Bellemann ME, Brix G. Performance of the whole-body PET scanner ECAT EXACT HR+ following the IEC standard. IEEE Trans Nucl Sci 1997;44:1172–9.CrossRef

28.

Boellaard R, van Lingen A, van Balen SC, Hoving BG, Lammertsma AA. Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med 2001;28:81–9.PubMedCrossRef

29.

Greuter HN, van Ophemert PL, Luurtsema G, van Berckel BN, Franssen EJ, Windhorst BD, et al. Optimizing an online SPE-HPLC method for analysis of (R)-[11C]1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide [(R)-[11C]PK11195] and its metabolites in humans. Nucl Med Biol 2005;32:307–12.PubMedCrossRef

30.

Watson CC. New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci 2004;47:1587–94.CrossRef

31.

Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab 2001;21:635–52.PubMedCrossRef

32.

Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 2006;34:392–404PubMedCrossRef

33.

Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19:716–23.CrossRef

Title: Quantification of (R)-[11C]PK11195 binding in rheumatoid arthritis
Authors: M. A. Kropholler
R. Boellaard
E. H. Elzinga
C. J. van der Laken
K. Maruyama
R. W. Kloet
A. E. Voskuyl
B. A. C. Dijkmans
A. A. Lammertsma
Publication date: 01-04-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0987-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quantification of (R)-[¹¹C]PK11195 binding in rheumatoid arthritis

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2009

Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosis

Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target

Kinetic modelling of [11C]flumazenil using data-driven methods

Functional neuroimaging in Hashimoto’s encephalitis: a physiopathological imaging?

Parametric renal blood flow imaging using [15O]H2O and PET

Giuliano Mariani, Armando E. Giuliano, William H. Strauss: Radioguided surgery: a comprehensive team approach